UNASYN is an injectable antibacterial combination consisting of the semisynthetic antibiotic ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium for intravenous and intramuscular administration.
Ampicillin sodium is derived from the penicillin nucleus, 6-aminopenicillanic acid.
UNASYN is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below.
Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli,
Klebsiella spp. (including K. pneumoniae
), Proteus mirabilis,
Bacteroides fragilis, Enterobacter spp., and Acinetobacter calcoaceticus.
NOTE: For information on use in pediatric patients see
Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae
), Bacteroides spp. (including B. fragilis), and Enterobacter spp.
Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli,
and Bacteroides spp. (including B. fragilis
While UNASYN is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with UNASYN due to its ampicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to UNASYN should not require the addition of another antibiotic.
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to UNASYN.
Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. Once the results are known, therapy should be adjusted if appropriate.
To reduce the development of drug-resistant bacteria and maintain effectiveness of UNASYN and other antibacterial drugs, UNASYN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Published Studies Related to Unasyn (Ampicillin / Sulbactam)
Ampicillin/sulbactam versus cefuroxime as antimicrobial prophylaxis for cesarean delivery: a randomized study. [2010.11.30]
BACKGROUND: The efficacy and safety of a single dose of ampicillin/sulbactam compared to a single dose of cefuroxime at cord clamp for prevention of post-cesarean infectious morbidity has not been assessed... CONCLUSIONS: Ampicillin/sulbactam was as safe and effective as cefuroxime when administered for the prevention of infections following cesarean delivery. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT01138852.
Clindamycin versus Unasyn in the treatment of facial cellulitis of odontogenic origin in children. [2007.03]
The study was undertaken to characterize the microbiology of dental abscesses in children and to compare clindamycin and ampicillin/sulbactam in the treatment of facial cellulitis of odontogenic origin. Sixty children with acute facial cellulitis of dental origin underwent surgery (extraction or root canal procedure) within 24 hours of presentation...
High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. 
The increased incidence of multidrug-resistant (MDR) Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients poses a severe therapeutic problem. The aim of this study was to evaluate the efficacy and safety of 2 high-dose treatment regimens of ampicillin-sulbactam (A/S) for MDR Acinetobacter baumannii VAP...
The value of chemoprophylaxis against Enterococcus species in elective cholecystectomy: a randomized study of cefuroxime vs ampicillin-sulbactam. [2006.12]
HYPOTHESIS: Cephalosporins are widely used and considered to be effective as prophylaxis in biliary surgery. Nevertheless, they lack activity against enterococci. We conducted a study to compare the efficacy of ampicillin-sulbactam vs cefuroxime in preventing surgical site infections following elective cholecystectomy... CONCLUSIONS: A single dose of ampicillin-sulbactam favored better compared with cefuroxime for prevention of postoperative surgical site infections due to Enterococcus species after elective cholecystectomy. Ampicillin-sulbactam may be a better agent for antimicrobial prophylaxis in high-risk patients undergoing elective cholecystectomy, especially in a setting where the incidence of enterococcal infections is higher.
Cefepime vs. Ampicillin/Sulbactam and Aztreonam as antibiotic prophylaxis in neurosurgical patients with external ventricular drain: result of a prospective randomized controlled clinical trial. [2006.06]
CONCLUSION: Single board spectrum antibiotic prophylaxis with Cefepime was an effective alternative regimen for neurosurgical patients with an EVD in situ.
Clinical Trials Related to Unasyn (Ampicillin / Sulbactam)
The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP) [Completed]
Unasyn-S 12g/day (3 g four times a day) is the commonly used dosage depending on the
severity for US, EU, China, Taiwan and Korea for over 20 years, however, Unasyn-S 12g/day
has not yet been approved in Japan. The purpose of this trial is to evaluate the clinical
efficacy and safety in Japanese adult subjects with community acquired pneumonia receiving
ampicillin sodium/sulbactam sodium, 12g/day (3 g four times a day ) IV.
Drug Use Investigation Of Sulbactam/Ampicillin (UNASYN) 12g (Regulatory Post Marketing Commitment Plan) [Active, not recruiting]
The purpose of the survey is to study the followings under practical use, regarding the
safety and effectiveness in high-dose administration (exceeding 6 g per day) of UNASYN-S and
UNASYN-S KIT for intravenous use (UNASYN).
1. Adverse Drug Reaction(s) that cannot be expected from precautions (Unexpected Adverse
2. Incidence status of adverse drug reactions
3. Factors that may affect the safety and effectiveness
Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients [Suspended]
This study seeks to assess whether coma patients really benefit from the use of antibiotics
as a prophylactic for reducing the incidence of early ventilator-associated pneumonia in
this population group. For this we consider the use of ampicillin sulbactam antibiotic which
has a low ability to induce resistance, efficacy and safety observed during the time that
has been used, even in patients with neurosurgical pathology, and to be broadly available in
Our hypothesis is that neurological patients in coma state, requiring mechanical
ventilation, the application of antibiotic prophylaxis compared with placebo reduces the
incidence of early ventilator-associated pneumonia.
Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections [Completed]
The purpose of this study is to compare the safety and efficacy of the antibiotic
tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavulanate in the
treatment of a complicated skin and/or skin structure infection (cSSSI).
T.E.A. Study Three Days Ertapenem Versus Three Days Ampicillin- Sulbactam [Completed]
The aim of the study was to compare the activity (efficacy and safety) of Ertapenem
administered according to a short treatment for three days versus a short treatment for
three days with AS in patients with an community acquired IAI of mild to moderate severity.
Reports of Suspected Unasyn (Ampicillin / Sulbactam) Side Effects
Toxic Skin Eruption (8),
Pneumonia Aspiration (4),
Hepatic Enzyme Increased (4),
Tremor (4), more >>
Page last updated: 2011-12-09